Clinical trials: Alzheimer's Disease, Healthy Volunteer, open to volunteers
Alzheimer Disease, Amyloid
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein…
- Conditions
- Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
- Trial name
- NCT07787169
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with…
- Trial name
- NCT07780383
- Testing
- BMS-986446
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08161842) and how it is processed by the body. This is the first time PF-08161842 will be given to people.
- Trial name
- NCT07897708
- Testing
- PF-08161842
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Pfizer
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
This is a Phase 1/1b, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL921 in healthy…
- Trial name
- NCT07758595
- Testing
- DNL921
- Where
- United Kingdom
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Healthy Volunteers, Alzheimer Disease
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
- Trial name
- NCT07787182
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Alzheimer Disease
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
- Trial name
- NCT07843459
- Testing
- LY4560736, Florbetapir F18, Florbetaben F 18
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD)
Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)
The study aims to phenotype hearing in patients with early stage of neurodegenerative disorders to explore the prevalence of various hearing disorders in comparison to a control population.
- Conditions
- Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD), Healthy Participants
- Trial name
- SAPHIR (NCT07083089)
- Testing
- Thorough Hearing assessment
- Where
- 4 sites in France
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- Cilcare SAS
Alzheimer Disease, Mild Cognitive Impairment
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
The goal of this clinical trial is to evaluate an investigational ultralow dose Positron Emission Tomography (PET) imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers
- Trial name
- NCT07012993
- Testing
- 18F-Florbetapir or 18F-Flutemetamol
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz
Healthy
A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants
This trial is a randomized, double-blind, placebo-controlled, single- and multiple-oral administration, phase 1 clinical trial to investigate the safety, tolerability, and pharmacokinetics of AS-S603 in healthy Korean or…
- Trial name
- NCT06786676
- Testing
- AS-S603
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Amyloid Solution Inc
Alzheimer Disease
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the…
- Trial name
- NCT06535308
- Testing
- BnH-015B 5 mg, BnH-015B 10 mg, BnH-015B 20 mg
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- BnH Research
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to…
- Trial name
- NCT07489599
- Testing
- QLH2405
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Alzheimer s Disease, Mild Cognitive Impairment
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Trial name
- NCT07169630
- Testing
- 18F-PF974, 18F-florbetaben
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Amyloid, Cardiac Amyloidosis
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
[18F]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene ([18F]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid.
- Conditions
- Amyloid, Cardiac Amyloidosis, Amyloidosis, Healthy Subjects
- Trial name
- NCT07232459
- Testing
- [18F]FT8
- Where
- 3 sites in China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Alzheimer Disease, Alzheimer Disease, Early Onset
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild…
- Trial name
- NCT07221344
- Testing
- ARO-MAPT-SC
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Alzheimer's Disease, Mild Cognitive Impairment
Wisconsin Brain Donor Program
The Wisconsin Brain Donor Program (WBDP) stores brain and other tissues/samples (e.g. blood and CSF) from deceased individuals who have participated in longitudinal research studies, as well as other select participants.
- Trial name
- WBDP (NCT00585572)
- Where
- United States
- Volunteers
- 9,999 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Alzheimer's Disease Psychosis, Parkinson Disease Psychosis
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.
- Conditions
- Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06793995
- Testing
- LY03017
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.